Effects of Surgery Combined with Different Chemotherapy on Matrix Metalloproteinase-9 and Tissue Inhibitors of Metalloproteinase-1 in Children with Neuroblastoma

Table 2

General data (mean ± SD (n, %)).

General data		Group A (n = 50)	Group B (n = 42)	χ^2/t
Gender				0.670	0.413
Male	61 (66.30)	35 (70.00)	26 (61.90)
Female	31 (33.70)	15 (30.00)	16 (38.10)
Age (years)	6.6 ± 1.9	7.2 ± 1.9	7.0 ± 2.3	0.457	0.649
INSS classification				1.271	0.260
III	38 (41.30)	18 (36.00)	20 (47.62)
IV	54 (58.70)	32 (64.00)	22 (52.38)
Primary site				2.125	0.713
Abdomen	24 (26.09)	10 (20.00)	14 (33.33)
Mediastinum	15 (16.30)	9 (18.00)	6 (14.29)
Paranephros	41 (44.57)	24 (48.00)	17 (40.48)
Spine	7 (7.61)	4 (8.00)	3 (7.14)
Others	5 (5.43)	3 (6.00)	2 (4.76)
Metastasis site				2.125	0.713
Bone	49 (53.26)	23 (46.00)	26 (61.90)
Lymph node	45 (48.91)	25 (50.00)	20 (47.62)
Liver	24 (26.09)	12 (24.00)	12 (28.57)
Intracranial	15 (16.30)	6 (12.00)	9 (21.43)
Others	16 (17.39)	7 (14.00)	9 (21.43)
INRG				Fisher	0.498
L1	2 (2.17)	2 (4.00)	0 (0.00)
L2	90 (97.83)	48 (96.00)	42 (100.00)
MYCN status				0.497	0.482
Amplified	71 (77.17)	40 (80.00)	31 (73.81)
Not amplified	21 (22.83)	10 (20.00)	11 (26.19)
2-year recurrence rate				0.885	0.347
Recurrence	18 (19.57)	8 (16.00)	10 (23.81)
Nonrecurrence	74 (80.43)	42 (84.00)	32 (76.19)
2-year prognosis				0.379	0.538
Survival	56 (60.87)	29 (58.00)	27 (64.29)
Death	36 (39.13)	21 (42.00)	15 (35.71)

INRG, the International Neuroblastoma Risk Group.